author(s)
Satheesh Kumar P and Karthiga

abstract
Sickle-cell Disease (SCD) is a neglected chronic disorder of increasing global health importance. Worldwide estimation of about 20-25 million sickle cell disease individuals and out of which 5-10 million are living in India¹. Still now, there is no complete treatment for SCD. Hematopoietic stem cell transplantation (HSCT) which is only hopeful treatment for SCD but this area is in beginning stag. Blood transfusion temporary treatment but has limitations, as most patients do not get a matched donor and unrelated donors have higher risks of complications, owing to immune reactions between the donor and the recipient. In this review we detail described about BCL11A silencing and how it will increases the fetal hemoglobin that is now emerging therapy for Sickle Cell Disease.